Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
XFOR

XFOR - X4 Pharmaceuticals Inc Stock Price, Fair Value and News

0.69USD+0.08 (+13.11%)Market Closed

Market Summary

XFOR
USD0.69+0.08
Market Closed
13.11%

XFOR Stock Price

View Fullscreen

XFOR RSI Chart

XFOR Valuation

Market Cap

115.9M

Price/Earnings (Trailing)

-0.9

Price/Sales (Trailing)

61.02

EV/EBITDA

-0.45

Price/Free Cashflow

-0.82

XFOR Price/Sales (Trailing)

XFOR Profitability

EBT Margin

-4294.00%

Return on Equity

-12.4K%

Return on Assets

-114.91%

Free Cashflow Yield

-121.52%

XFOR Fundamentals

XFOR Revenue

Revenue (TTM)

3.0M

XFOR Earnings

Earnings (TTM)

-128.9M

Earnings Growth (Yr)

-115.51%

Earnings Growth (Qtr)

-170.6%

Breaking Down XFOR Revenue

Last 7 days

23.2%

Last 30 days

-34.3%

Last 90 days

-48.5%

Trailing 12 Months

-63.7%

How does XFOR drawdown profile look like?

XFOR Financial Health

Current Ratio

3.71

XFOR Investor Care

Shares Dilution (1Y)

37.42%

Diluted EPS (TTM)

-0.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20205.7M5.2M3.2M3.0M
20183.6M3.3M3.7M3.2M
20172.8M3.1M3.5M3.9M
20160002.4M
20150002.2M

Tracking the Latest Insider Buys and Sells of X4 Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 10, 2024
woods keith
acquired
-
-
45,000
-
Jun 10, 2024
de craecker francoise
acquired
-
-
45,000
-
Jun 10, 2024
stewart murray
acquired
-
-
45,000
-
Jun 10, 2024
bridger gary
acquired
-
-
45,000
-
Jun 10, 2024
aliski william
acquired
-
-
45,000
-
Jun 10, 2024
lawton alison frances
acquired
-
-
45,000
-
Jun 10, 2024
mcgirr david w j
acquired
-
-
45,000
-
Jun 10, 2024
wyzga michael s
acquired
-
-
45,000
-
Mar 11, 2024
dibiase mary
sold
-13,590
0.882
-15,409
chief operating officer
Mar 11, 2024
taveras arthur
sold
-12,552
0.8818
-14,235
chief scientific officer

1–10 of 50

Which funds bought or sold XFOR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 10, 2024
CWM, LLC
added
12,914
1,000
1,000
-%
Jul 01, 2024
Legal & General Group Plc
unchanged
-
6,246
15,743
-%
Jun 24, 2024
LAZARI CAPITAL MANAGEMENT, INC.
unchanged
-
5,515
13,900
0.01%
May 23, 2024
RAELIPSKIE PARTNERSHIP
unchanged
-
551
1,390
-%
May 20, 2024
Virtu Financial LLC
sold off
-100
-107,000
-
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-40.09
-739
107,657
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-37.86
512
17,504
-%
May 15, 2024
AQR CAPITAL MANAGEMENT LLC
reduced
-78.14
-87,862
49,939
-%
May 15, 2024
Point72 Asset Management, L.P.
unchanged
-
358,475
903,500
-%
May 15, 2024
ARMISTICE CAPITAL, LLC
sold off
-100
-1,623,340
-
-%

1–10 of 46

Are Funds Buying or Selling XFOR?

Are funds buying XFOR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own XFOR
No. of Funds

Unveiling X4 Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
acorn bioventures, l.p.
4.8%
8,205,816
SC 13G
Feb 14, 2024
lincoln park capital fund, llc
947%
1,600,136
SC 13G/A
Feb 14, 2024
orbimed advisors llc
6.7%
11,494,437
SC 13G/A
Feb 13, 2024
bain capital life sciences fund, l.p.
9.99%
16,915,784
SC 13G/A
Feb 07, 2024
blackrock inc.
4.9%
8,160,747
SC 13G/A
Jan 31, 2024
blackrock inc.
5.0%
8,417,524
SC 13G
Jan 16, 2024
millennium management llc
1.0%
1,664,317
SC 13G/A
Jan 08, 2024
empery asset management, lp
2.65%
4,549,605
SC 13G/A
Jun 16, 2023
millennium management llc
5.2%
8,268,816
SC 13G
May 26, 2023
growth equity opportunities 18 vge, llc
9.99%
15,742,792
SC 13D/A

Recent SEC filings of X4 Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jun 27, 2024
8-K
Current Report
Jun 11, 2024
8-K
Current Report
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading

Peers (Alternatives to X4 Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
47.1B
6.8B
-17.23% -2.46%
-7.89
6.87
-64.45% -224.75%
33.0B
2.0B
67.01% 29.40%
-99.52
16.5
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
15.9B
2.5B
0.02% -1.58%
77.53
6.44
13.74% 186.89%
14.0B
3.8B
4.74% -0.56%
18.77
3.71
8.58% 129.81%
MID-CAP
5.0B
107.9M
-2.22% 48.86%
-9.2
48.09
54.84% -28.31%
4.7B
524.1M
-9.01% -54.24%
-11.31
9.01
394.93% 39.61%
4.0B
251.0M
18.93% 13.89%
-13.54
15.99
73.58% -86.73%
3.5B
240.7M
14.65% -16.72%
-7.42
12.77
-1.03% -213.92%
2.9B
813.8M
17.43% -31.75%
-1.7K
3.58
56.43% 98.83%
1.8B
996.6M
-22.65% 38.54%
-4.56
1.82
-26.66% 65.49%
SMALL-CAP
1.9B
411.3M
4.82% 27.42%
29.58
4.68
60.38% -34.49%
570.7M
881.7K
6.14% 580.25%
-16.91
481.06
-77.61% 33.36%
286.3M
4.2M
13.80% 73.74%
-2.29
68.83
-66.30% 48.24%
18.6M
2.1M
-12.55% 263.94%
-0.8
7.61
-13.45% 69.54%

X4 Pharmaceuticals Inc News

Latest updates
MarketBeat28 Jun 202407:33 pm

X4 Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2020Q42020Q32020Q22020Q12018Q42018Q32018Q22018Q12017Q42017Q32017Q22017Q12016Q42015Q4
Revenue----3.000.002.001.000.001.002.001.001.00--
Operating Expenses4.0%18.0017.0015.0014.0013.009.006.00-------
  S&GA Expenses-4.3%5.006.005.005.003.002.002.00-------
  R&D Expenses8.1%12.0011.009.009.005.006.005.00-------
Interest Expenses3.3%1.001.001.001.000.000.000.00-------
Income Taxes----0.00----------
Earnings Before Taxes-5.5%-18.40-17.45-15.14-10.99----------
Net Income-5.5%-18.40-17.45-15.14-11.14-9.36-8.60-6.03-------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-23.8%11214717317312415611381.0010011712114216112313314315416111013463.00
  Current Assets-28.5%87.0012214814898.0012986.0053.0071.0088.0081.0010112083.0094.0011012212979.0097.0026.00
    Cash Equivalents-39.0%60.0099.0013213694.0012381.0049.0068.0082.0078.0096.0011781.0089.0010411512876.0090.0022.00
  Net PPE-0.4%1.001.001.001.001.001.001.001.001.002.002.002.002.001.001.000.000.000.000.000.000.00
  Goodwill0%17.0017.0017.0017.0017.0017.0017.0017.0017.0017.0027.0027.0027.0027.0027.0027.0027.0027.0027.0027.0027.00
Liabilities15.6%11196.0010610673.0082.0052.0051.0050.0053.0052.0052.0054.0050.0043.0038.0035.0031.0030.0037.0033.00
  Current Liabilities3.0%24.0023.0025.0022.0019.0022.0029.0022.0015.0014.0013.0013.0015.0012.0013.0011.008.009.008.0013.0016.00
    LT Debt, Current----1.001.001.0015.009.003.001.001.00--------4.005.00
Shareholder's Equity-98.0%1.0051.0068.0068.0052.0074.0062.0030.0050.0064.0069.0087.0010573.0090.0010511912979.0096.0029.00
  Retained Earnings-10.8%-529-477-458-456-400-376-347-326-304-282-252-232-212-194-175-158-143-132-121-103-90.11
  Additional Paid-In Capital0.3%531529526524452451410356355347321320318267266263262261200200120
Shares Outstanding0.3%16816716516414612283.0035.0034.0026.0027.0024.00---------
Float----318---30.00---158---145---184-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-454.1%-33,6009,489-68,800-47,900-26,512-19,093-19,306-18,474-20,229-19,053-14,211-19,197-18,444-17,504-14,328-11,459-15,527-9,241-12,772-14,292-11,750
  Share Based Compensation-31.5%1,7392,5392,3612,1421,6451,1071,1111,5221,4591,6091,5161,7971,2581,3982,2441,173613664691433262
Cashflow From Investing-10.1%-5,322-4,833-5,157-4,884-9.00-34.00-9.00-38.00-22.00-13.00-20.00-86.00-496-302-496-9.00-55521.00815-10.0026,406
Cashflow From Financing-100.0%-97.0021,20569,338-2,12460,64451,977-3474,95624,570-4,442-92455,0417,629-28465.004,98460,284-6,41486,678113
  Buy Backs-----443----------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

XFOR Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 19,854$ 22,063
Selling, general and administrative17,4357,241
Total operating expenses37,28929,304
Loss from operations(37,289)(29,304)
Other (expense) income, net:  
Interest income1,066835
Interest expense(1,874)(1,109)
Other income, net105123
Total other (expense) income, net(14,458)5,288
Loss before provision for income taxes(51,747)(24,016)
Provision for income taxes194
Net loss$ (51,766)$ (24,020)
Net loss per share attributable to common stockholders—basic$ (0.26)$ (0.16)
Net loss per share attributable to common stockholders—diluted$ (0.26)$ (0.16)
Weighted average shares of common stock outstanding—diluted199,991,597145,967,476
Weighted average shares of common stock outstanding—basic199,991,597145,967,476
Supplemental Income Statement Elements [Abstract]  
Change in unrealized loss related to available-for-sale debt securities$ (36)$ 0
Comprehensive loss(51,802)(24,020)
Warrant Liability  
Other (expense) income, net:  
Derivative, gain (loss) on derivative, net$ (13,755)$ 5,439

XFOR Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 60,493$ 99,216
Marketable securities20,37615,000
Research and development incentive receivable702562
Prepaid expenses and other current assets5,7627,298
Total current assets87,333122,076
Property and equipment, net742745
Goodwill17,35117,351
Right-of-use assets5,2645,650
Other assets1,4921,436
Total assets112,182147,258
Current liabilities:  
Accounts payable8,9358,947
Accrued expenses13,47312,816
Current portion of lease liability1,1331,099
Total current liabilities23,54122,862
Long-term debt, including accretion, net of discount54,82454,570
Lease liabilities2,3182,612
Warrant liability (Note 4)29,43815,683
Other liabilities1,025432
Total liabilities111,14696,159
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Common stock, $0.001 par value, 500,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 167,937,781 and 167,434,595 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively168167
Additional paid-in capital530,694528,956
Accumulated other comprehensive loss(155)(119)
Accumulated deficit(529,671)(477,905)
Total stockholders’ equity1,03651,099
Total liabilities and stockholders’ equity$ 112,182$ 147,258
XFOR
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEx4pharma.com
 INDUSTRYBiotechnology
 EMPLOYEES40

X4 Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for X4 Pharmaceuticals Inc? What does XFOR stand for in stocks?

XFOR is the stock ticker symbol of X4 Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of X4 Pharmaceuticals Inc (XFOR)?

As of Thu Jul 11 2024, market cap of X4 Pharmaceuticals Inc is 115.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XFOR stock?

You can check XFOR's fair value in chart for subscribers.

What is the fair value of XFOR stock?

You can check XFOR's fair value in chart for subscribers. The fair value of X4 Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of X4 Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XFOR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is X4 Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether XFOR is over valued or under valued. Whether X4 Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact X4 Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XFOR.

What is X4 Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 11 2024, XFOR's PE ratio (Price to Earnings) is -0.9 and Price to Sales (PS) ratio is 61.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XFOR PE ratio will change depending on the future growth rate expectations of investors.